L’Oreal Settles With FTC Over Gene-Related Anti-Aging Skin Care Claims
This article was originally published in The Tan Sheet
Executive Summary
A proposed consent agreement with FTC bars L’Oreal USA from claiming its Lancome and L’Oreal Paris skin-care products target users’ genes with anti-aging benefits. The settlement, subject to public comment and final FTC approval, follows a 2012 FDA warning that cited some of the same marketing claims.
You may also be interested in...
Class-Actions Increasing As Fallout From Regulatory Action
Using marketing claims that overstep cosmetic boundaries can land firms in class-action suits that sap resources and drag on for years, attorneys noted at the ACI Legal, Regulatory and Compliance Forum on Cosmetics. Speakers provided examples and tips for staying out of court.
FDA Warns Lancome For Gene/Stem-Cell Claims: A Signal To Marketplace?
Claims for L’Oreal’s Lancome brand’s Genifique anti-aging line identify the products as drugs, FDA says. The agency cites claims that the brand’s technology “boosts the activity of genes” and “has been shown to improve the condition” around stem cells – language not unique in the anti-aging cosmeceutical market.
Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat
Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.